Pathfinder Cell Therapy, Inc. (PFND)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2014 | 106 Thousand USD | -31.61% |
| 2013 | 155 Thousand USD | -56.46% |
| 2012 | 356 Thousand USD | -44.72% |
| 2011 | 644 Thousand USD | 344.14% |
| 2010 | 145 Thousand USD | -88.12% |
| 2009 | 1.22 Million USD | -63.34% |
| 2008 | 3.33 Million USD | -1.22% |
| 2007 | 3.37 Million USD | -19.29% |
| 2006 | 4.17 Million USD | 283.3% |
| 2005 | 1.09 Million USD | -51.77% |
| 2004 | 2.26 Million USD | 122.88% |
| 2003 | 1.01 Million USD | 97.28% |
| 2002 | 514 Thousand USD | 14.48% |
| 2001 | 449 Thousand USD | -53.52% |
| 2000 | 966 Thousand USD | 21.05% |
| 1999 | 798 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2015 Q3 | 39 Thousand USD | -20.41% |
| 2015 Q1 | 86 Thousand USD | -18.87% |
| 2015 Q2 | 49 Thousand USD | -43.02% |
| 2014 Q3 | 70 Thousand USD | -4.11% |
| 2014 Q4 | 106 Thousand USD | 51.43% |
| 2014 Q1 | 142 Thousand USD | -8.39% |
| 2014 FY | 106 Thousand USD | -31.61% |
| 2014 Q2 | 73 Thousand USD | -48.59% |
| 2013 Q2 | 161 Thousand USD | -49.37% |
| 2013 Q1 | 318 Thousand USD | -10.67% |
| 2013 Q3 | 208 Thousand USD | 29.19% |
| 2013 Q4 | 155 Thousand USD | -25.48% |
| 2013 FY | 155 Thousand USD | -56.46% |
| 2012 Q4 | 356 Thousand USD | -8.01% |
| 2012 Q2 | 433 Thousand USD | -5.25% |
| 2012 FY | 356 Thousand USD | -44.72% |
| 2012 Q1 | 457 Thousand USD | -29.04% |
| 2012 Q3 | 387 Thousand USD | -10.62% |
| 2011 Q3 | 1.6 Million USD | 481.16% |
| 2011 Q2 | 276 Thousand USD | 49.19% |
| 2011 Q1 | 185 Thousand USD | 27.59% |
| 2011 FY | 644 Thousand USD | 344.14% |
| 2011 Q4 | 644 Thousand USD | -59.85% |
| 2010 Q2 | 567 Thousand USD | -48.22% |
| 2010 FY | 145 Thousand USD | -88.12% |
| 2010 Q4 | 145 Thousand USD | -21.62% |
| 2010 Q1 | 1.09 Million USD | -10.32% |
| 2010 Q3 | 185 Thousand USD | -67.37% |
| 2009 Q2 | 1.4 Million USD | -44.0% |
| 2009 Q1 | 2.5 Million USD | -24.74% |
| 2009 Q3 | 1.3 Million USD | -6.91% |
| 2009 FY | 1.22 Million USD | -63.34% |
| 2009 Q4 | 1.22 Million USD | -6.58% |
| 2008 FY | 3.33 Million USD | -1.22% |
| 2008 Q2 | 1.29 Million USD | -44.86% |
| 2008 Q1 | 2.34 Million USD | -30.52% |
| 2008 Q4 | 3.33 Million USD | -20.58% |
| 2008 Q3 | 4.19 Million USD | 224.61% |
| 2007 FY | 3.37 Million USD | -19.29% |
| 2007 Q2 | 2.18 Million USD | -34.66% |
| 2007 Q4 | 3.37 Million USD | -15.55% |
| 2007 Q1 | 3.34 Million USD | -19.89% |
| 2007 Q3 | 3.99 Million USD | 82.58% |
| 2006 Q2 | 5.14 Million USD | 756.67% |
| 2006 Q4 | 4.17 Million USD | -4.98% |
| 2006 FY | 4.17 Million USD | 283.3% |
| 2006 Q1 | 600 Thousand USD | -44.95% |
| 2006 Q3 | 4.39 Million USD | -14.46% |
| 2005 Q2 | 1.86 Million USD | -24.45% |
| 2005 FY | 1.09 Million USD | -51.77% |
| 2005 Q4 | 1.09 Million USD | -11.38% |
| 2005 Q3 | 1.23 Million USD | -33.87% |
| 2005 Q1 | 2.46 Million USD | 8.94% |
| 2004 Q4 | 2.26 Million USD | -6.19% |
| 2004 FY | 2.26 Million USD | 122.88% |
| 2004 Q3 | 2.4 Million USD | -15.33% |
| 2004 Q2 | 2.84 Million USD | -14.74% |
| 2004 Q1 | 3.33 Million USD | 229.09% |
| 2003 Q3 | 1.17 Million USD | -21.3% |
| 2003 Q1 | 1.09 Million USD | 112.84% |
| 2003 FY | 1.01 Million USD | 97.28% |
| 2003 Q4 | 1.01 Million USD | -13.7% |
| 2003 Q2 | 1.49 Million USD | 36.47% |
| 2002 Q4 | 514 Thousand USD | 8.67% |
| 2002 FY | 514 Thousand USD | 14.48% |
| 2002 Q1 | 747 Thousand USD | 66.37% |
| 2002 Q2 | 652 Thousand USD | -12.72% |
| 2002 Q3 | 473 Thousand USD | -27.45% |
| 2001 FY | 449 Thousand USD | -53.52% |
| 2001 Q4 | 449 Thousand USD | 73.36% |
| 2001 Q2 | 267 Thousand USD | -55.5% |
| 2001 Q1 | 600 Thousand USD | -37.89% |
| 2001 Q3 | 259 Thousand USD | -3.0% |
| 2000 Q4 | 966 Thousand USD | 2741.18% |
| 2000 Q3 | 34 Thousand USD | -76.55% |
| 2000 FY | 966 Thousand USD | 21.05% |
| 2000 Q1 | 453 Thousand USD | 0.0% |
| 2000 Q2 | 145 Thousand USD | -67.99% |
| 1999 FY | 798 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -4488.745% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 94.587% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 98.996% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 80.801% |
| Rebus Holdings, Inc. | 5000.00 USD | -2020.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.919% |
| Qrons Inc. | 420.00 USD | -25138.095% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 86.245% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.621% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 77.942% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.112% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.727% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.532% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -38.827% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.901% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 92.598% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -46.48% |
| Mesoblast Limited | 667.9 Million USD | 99.984% |
| Marizyme, Inc. | 22.01 Million USD | 99.519% |
| Genus plc | 1.02 Billion USD | 99.99% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 92.196% |
| Pharming Group N.V. | 462.85 Million USD | 99.977% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 96.8% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 78.759% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 83.094% |
| ContraFect Corporation | 20.67 Million USD | 99.487% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 72.846% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 72.264% |
| IMV Inc. | 31.33 Million USD | 99.662% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 97.443% |
| MultiCell Technologies, Inc. | 126.22 USD | -83880.352% |
| ONE Bio Corp. | 70.08 Million USD | 99.849% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 88.72% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.918% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 75.447% |
| Q BioMed Inc. | 3.51 Million USD | 96.985% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.699% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 59.43% |
| Biomind Labs Inc. | 73.81 Thousand USD | -43.594% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.976% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 92.684% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.647% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 96.14% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 84.582% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 95.928% |
| GB Sciences, Inc. | 103.44 Thousand USD | -2.473% |
| Alpha Cognition Inc. | 2.45 Million USD | 95.677% |
| HST Global, Inc. | 1526.00 USD | -6846.265% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 89.271% |
| Halberd Corporation | 10.13 Thousand USD | -946.294% |
| Enzolytics Inc. | 361.7 Million USD | 99.971% |
| Agentix Corp. | 261.39 Thousand USD | 59.448% |
| Resverlogix Corp. | 8.11 Million USD | 98.694% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 94.355% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.778% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 83.429% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -365.3% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 98.816% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.563% |
| Zenith Capital Corp. | 7410.00 USD | -1330.499% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.997% |
| Ember Therapeutics, Inc. | 184.00 USD | -57508.696% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 67.061% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 59.444% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 88.577% |
| Kadimastem Ltd | 2.3 Million USD | 95.399% |
| Helix BioMedix, Inc. | 3.02 Million USD | 96.496% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.799% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.272% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -85.659% |
| LadRx Corporation | 2.3 Million USD | 95.407% |
| Cell Source, Inc. | 195.17 Thousand USD | 45.689% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 70.024% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 70.024% |
| NovAccess Global Inc. | 62.24 Thousand USD | -70.287% |
| Affymax, Inc. | 7.44 Million USD | 98.576% |
| Itoco Inc. | 1.4 Million USD | 92.429% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -10.813% |
| Mobile Lads Corp. | 52.00 USD | -203746.154% |
| CytoDyn Inc. | 11.13 Million USD | 99.048% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 25.86% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -492.841% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 72.501% |
| SYBLEU INC | 330.46 Thousand USD | 67.924% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 74.11% |
| International Stem Cell Corporation | 5.39 Million USD | 98.033% |
| Bioxytran, Inc. | 137.63 Thousand USD | 22.986% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.293% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.361% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -34.177% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 87.741% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.59% |
| Neutra Corp. | 2851.00 USD | -3617.994% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.673% |
| PureTech Health plc | 693.97 Million USD | 99.985% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 98.687% |
| IXICO plc | 15.84 Million USD | 99.331% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 98.72% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.897% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.968% |